Jul 29
|
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
|
Jul 28
|
AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776
|
Jul 27
|
AstraZeneca Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Jul 26
|
FDA committee proposes overhaul of perioperative lung cancer trials
|
Jul 26
|
3 Surprisingly Underrated Stocks to Buy Right Now
|
Jul 26
|
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
|
Jul 26
|
Top 3 UK Stocks Estimated To Be Undervalued In July 2024
|
Jul 26
|
AstraZeneca CEO talks dual supply chain strategy
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
Jul 25
|
US economy keeps growing, Astrazeneca CEO describes challenges: Catalysts
|
Jul 25
|
AstraZeneca CEO: We're building '2 supply chains' to avoid impact of US-China tensions
|
Jul 25
|
Top Midday Stories: US Advance Q2 GDP Rises; Initial Jobless Claims Drop; Ford Earnings Fall; TotalEnergies' Lower Results; AbbVie Raises Guidance; IBM, ServiceNow Report Higher Results
|
Jul 25
|
Why AstraZeneca Stock Is Sliding Today
|
Jul 25
|
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
|
Jul 25
|
Why AstraZeneca's CEO isn't worried about costs
|
Jul 25
|
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
|
Jul 25
|
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
|
Jul 25
|
NHS spending rules risk depriving Britain of new medicine, warns AstraZeneca boss
|
Jul 25
|
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
|
Jul 25
|
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
|